Larimar Therapeutics Inc (LRMR NASDAQ) stock market data APIs
$2.716
0(0%)
as of November 12, 2026
Try our APIs with
free plan!
Larimar Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Prev. Close
2.716
Open
2.6828
High
2.7761
Low
2.4975
52 wk Range
1.915-6.42
Market Cap
280 M
Shares Outstanding
104 M
EPS
-0.61
Beta
0.695
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Larimar Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Larimar Therapeutics Inc data using free add-ons & libraries
Get Larimar Therapeutics Inc Fundamental Data
Larimar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -178 684 992
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Larimar Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-18
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Larimar Therapeutics Inc News
New
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such inv...
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple. On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License A...
Thursday 7/9 Insider Buying Report: LRMR, EVMN
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Get Larimar Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.